Screener
Lexicon Pharmaceuticals LXRX Total Operating Expenses
Discontinued — last reported Q1 '23
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed May 4, 2023.
- Filed
- May 4, 2023
- Fiscal quarter
- Q1 FY2023
- Calendar quarter
- Q1 2023
- Accession
- 0001062822-23-000024
| Line item | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 |
|---|---|---|
| Operating expenses: | ||
| Research and development, including stock-based compensation of $1,203 and $1,032, respectively | 12,026 | 14,926 |
| Selling, general and administrative, including stock-based compensation of $2,212 and $1,740, respectively | 19,140 | 8,491 |
| Total operating expenses | 31,166 | 23,417 |
| Loss from operations | (31,142) | (23,380) |
| Interest expense | (1,821) | (110) |
| Interest and other income, net | 1,029 | 14 |
| Net loss | $(31,934) | $(23,476) |
Item 1. Financial Statements
FAQ
- What is Lexicon Pharmaceuticals's total operating expenses?
- Lexicon Pharmaceuticals (LXRX) reported total operating expenses of -$31.17M in Q1 2023.
- How has Lexicon Pharmaceuticals's total operating expenses changed year-over-year?
- Lexicon Pharmaceuticals's total operating expenses decreased by 233.1% year-over-year, from $23.42M to -$31.17M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Lexicon Pharmaceuticals's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude